Literature DB >> 8111707

The sensitivity of hyaluronan analysis of pleural fluid from patients with malignant mesothelioma and a comparison of different methods.

G Martensson1, A Thylen, U Lindquist, A Hjerpe.   

Abstract

BACKGROUND: Hyaluronan may be used as a marker for malignant mesothelioma, thus indicating its mesodermal origin.
METHODS: The sensitivity as a diagnostic test of three different methods for hyaluronan analyses of pleural fluid was examined in patients with biopsy-verified malignant pleural mesothelioma.
RESULTS: A quantitative high-performance liquid-chromatography (HPLC) method was performed on fluids from 43 patients. Using a cutoff level of 100 mg/l, higher levels were noted in 30 (70%) patients, with a median value of 220 mg/l (mean, 560 mg/l; range, 20-6600 mg/l). An identical median value (220 mg/l) was obtained with a radioassay method when simultaneously performed on paired samples from 21 patients (correlation coefficient, 0.91). A qualitative precipitation test using 0.5% cetylpyridinium chloride combined with a quantitative viscosimetric method was significantly less sensitive (P < 0.01).
CONCLUSION: Hyaluronan analyses is beneficial in distinguishing malignant mesothelioma if methods such as the evaluated HPLC or radioassay with a sensitivity of 70% toward mesothelioma are used and other known causes of elevated content are considered.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8111707     DOI: 10.1002/1097-0142(19940301)73:5<1406::aid-cncr2820730515>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Cytological diagnosis of malignant mesothelioma--improvement by additional analysis of hyaluronic acid in pleural effusions.

Authors:  L Welker; M Müller; O Holz; E Vollmer; H Magnussen; R A Jörres
Journal:  Virchows Arch       Date:  2007-02-15       Impact factor: 4.064

2.  Hyaluronan synthase expression in pleural malignant mesotheliomas.

Authors:  Naoki Kanomata; Tomoyuki Yokose; Tomoyuki Kamijo; Hiroyuki Yonou; Takahiro Hasebe; Naoki Itano; Koji Kimata; Atsushi Ochiai
Journal:  Virchows Arch       Date:  2005-02-25       Impact factor: 4.064

3.  Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma.

Authors:  Filip Mundt; Gustav Nilsonne; Sertaç Arslan; Karola Csürös; Gunnar Hillerdal; Huseyin Yildirim; Muzaffer Metintas; Katalin Dobra; Anders Hjerpe
Journal:  PLoS One       Date:  2013-08-21       Impact factor: 3.240

Review 4.  CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives.

Authors:  Lourdes Cortes-Dericks; Ralph Alexander Schmid
Journal:  Respir Res       Date:  2017-04-12

Review 5.  Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP.

Authors:  Gérard Zalcman; Guénaëlle Levallet; Fatéméh Dubois; Céline Bazille; Jérôme Levallet; Elodie Maille; Solenn Brosseau; Jeannick Madelaine; Emmanuel Bergot
Journal:  Target Oncol       Date:  2022-07-30       Impact factor: 4.864

6.  Significance of secretory leukocyte peptidase inhibitor in pleural fluid for the diagnosis of benign asbestos pleural effusion.

Authors:  Takumi Kishimoto; Yoko Kojima; Nobukazu Fujimoto
Journal:  Sci Rep       Date:  2021-06-21       Impact factor: 4.379

7.  Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma.

Authors:  Filip Mundt; Henrik J Johansson; Jenny Forshed; Sertaç Arslan; Muzaffer Metintas; Katalin Dobra; Janne Lehtiö; Anders Hjerpe
Journal:  Mol Cell Proteomics       Date:  2013-12-20       Impact factor: 5.911

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.